Baseline Characteristics of Study Cohort of Patients With Age-Standardized Annual Incidence of Spinal Metastases, and Average Annual Percent Change (AAPC) in the Incidence of Spine Metastasis SD Standard Deviation
| Year . | No. of Patients . | Age, years (SD) . | Male (%) . | Lung (%) . | Breast (%) . | Prostate (%) . | Gastrointestinal (%) . | Myeloma (%) . | Urological (%) . | Age—Standardized annual incidence of spinal metastases (95% CI)—/Million . | AAPC in spinal metastases incidence (95% CI), P-value . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2007–2019 | 37 375 | 64.4 (12.6) | 20 564 (55.0) | 10 150 (27.2) | 5958 (15.9) | 5814 (15.6) | 3146 (8.4) | 3061 (8.2) | 2759 (7.4) | — | 2.2 (1.4 to 3.0), P < .01 |
| 2007 | 2033 | 63.7 (12.8) | 1059 (52.1) | 626 (30.8) | 302 (14.9) | 228 (11.2) | 172 (8.5) | 192 (9.4) | 146 (7.2) | 229 (219–239) | |
| 2008 | 2203 | 63.7 (12.6) | 1206 (54.7) | 698 (31.7) | 295 (13.4) | 275 (12.5) | 195 (8.9) | 197 (8.9) | 139 (6.3) | 242 (232–252) | |
| 2009 | 2400 | 64.1 (12.6) | 1300 (54.2) | 692 (28.8) | 361 (15.0) | 320 (13.3) | 226 (9.4) | 203 (8.5) | 185 (7.7) | 257 (247–268) | |
| 2010 | 2450 | 64.3 (12.7) | 1365 (55.7) | 714 (29.1) | 385 (15.7) | 329 (13.4) | 205 (8.4) | 206 (8.4) | 199 (8.1) | 255 (245–265) | |
| 2011 | 2691 | 64.4 (12.9) | 1473 (54.7) | 805 (29.9) | 385 (14.3) | 375 (13.9) | 239 (8.9) | 219 (8.1) | 188 (7.0) | 273 (263–284) | |
| 2012 | 2828 | 64.3 (12.8) | 1548 (54.7) | 782 (27.7) | 443 (15.7) | 416 (14.7) | 249 (8.8) | 261 (9.2) | 187 (6.6) | 282 (272–293) | |
| 2013 | 2946 | 64.2 (12.7) | 1611 (54.7) | 796 (27.0) | 479 (16.3) | 434 (14.7) | 249 (8.5) | 223 (7.6) | 234 (7.9) | 285 (275–296) | |
| 2014 | 2987 | 64.4 (12.9) | 1622 (54.3) | 827 (27.7) | 505 (16.9) | 459 (15.4) | 250 (8.4) | 260 (8.7) | 191 (6.4) | 284 (273–294) | |
| 2015 | 3164 | 64.5 (12.5) | 1722 (54.4) | 825 (26.1) | 519 (16.4) | 522 (16.5) | 268 (8.5) | 257 (8.1) | 208 (6.6) | 293 (283–304) | |
| 2016 | 3380 | 64.8 (12.6) | 1921 (56.8) | 851 (25.2) | 554 (16.4) | 591 (17.5) | 277 (8.2) | 244 (7.2) | 278 (8.2) | 305 (295–316) | |
| 2017 | 3293 | 64.3 (12.6) | 1829 (55.5) | 800 (24.3) | 560 (17.0) | 561 (17.0) | 262 (8.0) | 247 (7.5) | 270 (8.2) | 291 (281–301) | |
| 2018 | 3412 | 64.8 (12.4) | 1912 (56.0) | 835 (24.5) | 556 (16.3) | 611 (17.9) | 280 (8.2) | 272 (8.0) | 250 (7.3) | 294 (284–304) | |
| 2019 | 3588 | 65.0 (12.3) | 1996 (55.6) | 899 (25.1) | 614 (17.1) | 693 (19.3) | 274 (7.6) | 280 (7.8) | 284 (7.9) | 302 (292–312) |
| Year . | No. of Patients . | Age, years (SD) . | Male (%) . | Lung (%) . | Breast (%) . | Prostate (%) . | Gastrointestinal (%) . | Myeloma (%) . | Urological (%) . | Age—Standardized annual incidence of spinal metastases (95% CI)—/Million . | AAPC in spinal metastases incidence (95% CI), P-value . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2007–2019 | 37 375 | 64.4 (12.6) | 20 564 (55.0) | 10 150 (27.2) | 5958 (15.9) | 5814 (15.6) | 3146 (8.4) | 3061 (8.2) | 2759 (7.4) | — | 2.2 (1.4 to 3.0), P < .01 |
| 2007 | 2033 | 63.7 (12.8) | 1059 (52.1) | 626 (30.8) | 302 (14.9) | 228 (11.2) | 172 (8.5) | 192 (9.4) | 146 (7.2) | 229 (219–239) | |
| 2008 | 2203 | 63.7 (12.6) | 1206 (54.7) | 698 (31.7) | 295 (13.4) | 275 (12.5) | 195 (8.9) | 197 (8.9) | 139 (6.3) | 242 (232–252) | |
| 2009 | 2400 | 64.1 (12.6) | 1300 (54.2) | 692 (28.8) | 361 (15.0) | 320 (13.3) | 226 (9.4) | 203 (8.5) | 185 (7.7) | 257 (247–268) | |
| 2010 | 2450 | 64.3 (12.7) | 1365 (55.7) | 714 (29.1) | 385 (15.7) | 329 (13.4) | 205 (8.4) | 206 (8.4) | 199 (8.1) | 255 (245–265) | |
| 2011 | 2691 | 64.4 (12.9) | 1473 (54.7) | 805 (29.9) | 385 (14.3) | 375 (13.9) | 239 (8.9) | 219 (8.1) | 188 (7.0) | 273 (263–284) | |
| 2012 | 2828 | 64.3 (12.8) | 1548 (54.7) | 782 (27.7) | 443 (15.7) | 416 (14.7) | 249 (8.8) | 261 (9.2) | 187 (6.6) | 282 (272–293) | |
| 2013 | 2946 | 64.2 (12.7) | 1611 (54.7) | 796 (27.0) | 479 (16.3) | 434 (14.7) | 249 (8.5) | 223 (7.6) | 234 (7.9) | 285 (275–296) | |
| 2014 | 2987 | 64.4 (12.9) | 1622 (54.3) | 827 (27.7) | 505 (16.9) | 459 (15.4) | 250 (8.4) | 260 (8.7) | 191 (6.4) | 284 (273–294) | |
| 2015 | 3164 | 64.5 (12.5) | 1722 (54.4) | 825 (26.1) | 519 (16.4) | 522 (16.5) | 268 (8.5) | 257 (8.1) | 208 (6.6) | 293 (283–304) | |
| 2016 | 3380 | 64.8 (12.6) | 1921 (56.8) | 851 (25.2) | 554 (16.4) | 591 (17.5) | 277 (8.2) | 244 (7.2) | 278 (8.2) | 305 (295–316) | |
| 2017 | 3293 | 64.3 (12.6) | 1829 (55.5) | 800 (24.3) | 560 (17.0) | 561 (17.0) | 262 (8.0) | 247 (7.5) | 270 (8.2) | 291 (281–301) | |
| 2018 | 3412 | 64.8 (12.4) | 1912 (56.0) | 835 (24.5) | 556 (16.3) | 611 (17.9) | 280 (8.2) | 272 (8.0) | 250 (7.3) | 294 (284–304) | |
| 2019 | 3588 | 65.0 (12.3) | 1996 (55.6) | 899 (25.1) | 614 (17.1) | 693 (19.3) | 274 (7.6) | 280 (7.8) | 284 (7.9) | 302 (292–312) |
Baseline Characteristics of Study Cohort of Patients With Age-Standardized Annual Incidence of Spinal Metastases, and Average Annual Percent Change (AAPC) in the Incidence of Spine Metastasis SD Standard Deviation
| Year . | No. of Patients . | Age, years (SD) . | Male (%) . | Lung (%) . | Breast (%) . | Prostate (%) . | Gastrointestinal (%) . | Myeloma (%) . | Urological (%) . | Age—Standardized annual incidence of spinal metastases (95% CI)—/Million . | AAPC in spinal metastases incidence (95% CI), P-value . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2007–2019 | 37 375 | 64.4 (12.6) | 20 564 (55.0) | 10 150 (27.2) | 5958 (15.9) | 5814 (15.6) | 3146 (8.4) | 3061 (8.2) | 2759 (7.4) | — | 2.2 (1.4 to 3.0), P < .01 |
| 2007 | 2033 | 63.7 (12.8) | 1059 (52.1) | 626 (30.8) | 302 (14.9) | 228 (11.2) | 172 (8.5) | 192 (9.4) | 146 (7.2) | 229 (219–239) | |
| 2008 | 2203 | 63.7 (12.6) | 1206 (54.7) | 698 (31.7) | 295 (13.4) | 275 (12.5) | 195 (8.9) | 197 (8.9) | 139 (6.3) | 242 (232–252) | |
| 2009 | 2400 | 64.1 (12.6) | 1300 (54.2) | 692 (28.8) | 361 (15.0) | 320 (13.3) | 226 (9.4) | 203 (8.5) | 185 (7.7) | 257 (247–268) | |
| 2010 | 2450 | 64.3 (12.7) | 1365 (55.7) | 714 (29.1) | 385 (15.7) | 329 (13.4) | 205 (8.4) | 206 (8.4) | 199 (8.1) | 255 (245–265) | |
| 2011 | 2691 | 64.4 (12.9) | 1473 (54.7) | 805 (29.9) | 385 (14.3) | 375 (13.9) | 239 (8.9) | 219 (8.1) | 188 (7.0) | 273 (263–284) | |
| 2012 | 2828 | 64.3 (12.8) | 1548 (54.7) | 782 (27.7) | 443 (15.7) | 416 (14.7) | 249 (8.8) | 261 (9.2) | 187 (6.6) | 282 (272–293) | |
| 2013 | 2946 | 64.2 (12.7) | 1611 (54.7) | 796 (27.0) | 479 (16.3) | 434 (14.7) | 249 (8.5) | 223 (7.6) | 234 (7.9) | 285 (275–296) | |
| 2014 | 2987 | 64.4 (12.9) | 1622 (54.3) | 827 (27.7) | 505 (16.9) | 459 (15.4) | 250 (8.4) | 260 (8.7) | 191 (6.4) | 284 (273–294) | |
| 2015 | 3164 | 64.5 (12.5) | 1722 (54.4) | 825 (26.1) | 519 (16.4) | 522 (16.5) | 268 (8.5) | 257 (8.1) | 208 (6.6) | 293 (283–304) | |
| 2016 | 3380 | 64.8 (12.6) | 1921 (56.8) | 851 (25.2) | 554 (16.4) | 591 (17.5) | 277 (8.2) | 244 (7.2) | 278 (8.2) | 305 (295–316) | |
| 2017 | 3293 | 64.3 (12.6) | 1829 (55.5) | 800 (24.3) | 560 (17.0) | 561 (17.0) | 262 (8.0) | 247 (7.5) | 270 (8.2) | 291 (281–301) | |
| 2018 | 3412 | 64.8 (12.4) | 1912 (56.0) | 835 (24.5) | 556 (16.3) | 611 (17.9) | 280 (8.2) | 272 (8.0) | 250 (7.3) | 294 (284–304) | |
| 2019 | 3588 | 65.0 (12.3) | 1996 (55.6) | 899 (25.1) | 614 (17.1) | 693 (19.3) | 274 (7.6) | 280 (7.8) | 284 (7.9) | 302 (292–312) |
| Year . | No. of Patients . | Age, years (SD) . | Male (%) . | Lung (%) . | Breast (%) . | Prostate (%) . | Gastrointestinal (%) . | Myeloma (%) . | Urological (%) . | Age—Standardized annual incidence of spinal metastases (95% CI)—/Million . | AAPC in spinal metastases incidence (95% CI), P-value . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2007–2019 | 37 375 | 64.4 (12.6) | 20 564 (55.0) | 10 150 (27.2) | 5958 (15.9) | 5814 (15.6) | 3146 (8.4) | 3061 (8.2) | 2759 (7.4) | — | 2.2 (1.4 to 3.0), P < .01 |
| 2007 | 2033 | 63.7 (12.8) | 1059 (52.1) | 626 (30.8) | 302 (14.9) | 228 (11.2) | 172 (8.5) | 192 (9.4) | 146 (7.2) | 229 (219–239) | |
| 2008 | 2203 | 63.7 (12.6) | 1206 (54.7) | 698 (31.7) | 295 (13.4) | 275 (12.5) | 195 (8.9) | 197 (8.9) | 139 (6.3) | 242 (232–252) | |
| 2009 | 2400 | 64.1 (12.6) | 1300 (54.2) | 692 (28.8) | 361 (15.0) | 320 (13.3) | 226 (9.4) | 203 (8.5) | 185 (7.7) | 257 (247–268) | |
| 2010 | 2450 | 64.3 (12.7) | 1365 (55.7) | 714 (29.1) | 385 (15.7) | 329 (13.4) | 205 (8.4) | 206 (8.4) | 199 (8.1) | 255 (245–265) | |
| 2011 | 2691 | 64.4 (12.9) | 1473 (54.7) | 805 (29.9) | 385 (14.3) | 375 (13.9) | 239 (8.9) | 219 (8.1) | 188 (7.0) | 273 (263–284) | |
| 2012 | 2828 | 64.3 (12.8) | 1548 (54.7) | 782 (27.7) | 443 (15.7) | 416 (14.7) | 249 (8.8) | 261 (9.2) | 187 (6.6) | 282 (272–293) | |
| 2013 | 2946 | 64.2 (12.7) | 1611 (54.7) | 796 (27.0) | 479 (16.3) | 434 (14.7) | 249 (8.5) | 223 (7.6) | 234 (7.9) | 285 (275–296) | |
| 2014 | 2987 | 64.4 (12.9) | 1622 (54.3) | 827 (27.7) | 505 (16.9) | 459 (15.4) | 250 (8.4) | 260 (8.7) | 191 (6.4) | 284 (273–294) | |
| 2015 | 3164 | 64.5 (12.5) | 1722 (54.4) | 825 (26.1) | 519 (16.4) | 522 (16.5) | 268 (8.5) | 257 (8.1) | 208 (6.6) | 293 (283–304) | |
| 2016 | 3380 | 64.8 (12.6) | 1921 (56.8) | 851 (25.2) | 554 (16.4) | 591 (17.5) | 277 (8.2) | 244 (7.2) | 278 (8.2) | 305 (295–316) | |
| 2017 | 3293 | 64.3 (12.6) | 1829 (55.5) | 800 (24.3) | 560 (17.0) | 561 (17.0) | 262 (8.0) | 247 (7.5) | 270 (8.2) | 291 (281–301) | |
| 2018 | 3412 | 64.8 (12.4) | 1912 (56.0) | 835 (24.5) | 556 (16.3) | 611 (17.9) | 280 (8.2) | 272 (8.0) | 250 (7.3) | 294 (284–304) | |
| 2019 | 3588 | 65.0 (12.3) | 1996 (55.6) | 899 (25.1) | 614 (17.1) | 693 (19.3) | 274 (7.6) | 280 (7.8) | 284 (7.9) | 302 (292–312) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
